Bacterial respiratory tract infection normally occurs in infants requiring early intubation in the emergency department (ED) for viral bronchiolitis, according to a study. However, respiratory bacterial codetection appears to shorten the duration of mechanical ventilation (MV) and length of stay (LOS) of these patients in the intensive care unit (ICU).
In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).
New drug applications approved by US FDA as of 01-15 February 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Using an interactive animated video to improve children’s cooperativeness during magnetic resonance imaging (MRI) is as good as using both regular and interactive videos, according to a Singapore study.
Early treatment with tumour necrosis factor (TNF) inhibitors lowers the risk of perianal fistulizing complications (PFCs) in children and teens compared with no immunosuppression or immunomodulators without TNF inhibitors in a post-hoc analysis of a prospective observational study.
An augmented reality mobile application (app), called the Paediatric Augmented Reality Scale (PARS), performs slightly better than the Broselow tape (BT) and Paediatric Advanced Weight Prediction in the Emergency Room extra-long and extra-large (PAWPER-XL) tape methods in estimating body weight of children, a Korea study has shown.
A high diet quality characterized by increased intake of fish and vegetables and limited consumption of sugary drinks at 1 year of age appears to offer protection against subsequent inflammatory bowel disease (IBD), as reported in a study.
The angiopoietin-like 3 inhibitor evinacumab appears to reduce low-density lipoprotein cholesterol (LDL-C) levels in children with homozygous familial hypercholesterolemia (HoFH) and persistently high LDL-C despite optimized therapy.